Portfolio Companies News
October 20, 2017Promising preliminary long-term dat...
Wilson Therapeutics (publ) announced today that preliminary data from the ongoing extension part of the Phase 2 trial with WTX101 (bis-choline tetrathiomolybdate), an investigational oral first-in-class copper-protein binding agent for the treatment of patients with Wilson Disease, will be presented... read more
October 19, 2017BONESUPPORT HOLDING AB (publ) – Q...
Lund, Sweden, 08:00 CEST 19 October 2017 – BONESUPPORT™ an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform, will publish its Q3 2017 Interim Repo... read more
October 17, 2017Onxeo Reports First Instance Decisi...
Paris (France), October 17, 2017 – 10 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” or the “Company”), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, t... read more
October 16, 2017Aprea Therapeutics Announces First ...
October 16, 2017—BOSTON, MA. and STOCKHOLM, SWEDEN, October 16, 2017 – Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, announced today that the first patients were enrolled in a Phase... read more
October 16, 2017Nexstim Plc is negotiating an assem...
Company announcement, Helsinki, 16 October 2017, at 9:00 am Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), a medical technology company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic and diagnostic applications, is negotiati... read more
July 14, 2017Q2 2017 General Market Overview
Since the start in 1996, HealthCap funds have invested in 108 portfolio companies.
41 of the portfolio companies have been taken public on nine different markets.
22 of the portfolio companies’ pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 7 companies with a valuation of USD 1 billion or more and 35 companies with a valuation of SEK 1 billion or more.